Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte’s Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.
Brightplex’s new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers. This innovative approach allows the simultaneous detection of several protein expressions and RNA transcripts, facilitating a more complete understanding of the complex molecular dynamics within the TME. The technology is particularly relevant when no or poor antibodies are available for a specific target. Complex cell phenotypes can still be analyzed by combining RNA transcripts and proteins. The featured speakers will showcase how this multimodal technology can significantly enhance biomarker studies.
This webinar is in line with the ever-growing need for biomarkers in clinical trials. Biomarkers serve as indispensable tools for patient stratification, treatment response monitoring and overall trial success. The integration of advanced multiplex IHC technology not only expedites the identification of relevant biomarkers but also provides a more comprehensive understanding of their spatial context within the TME.
This technology goes beyond conventional approaches, empowering researchers to decipher intricate cellular interactions and identify biomarkers with unprecedented precision. The webinar will showcase real-world case studies, illustrating how these advancements have already made an impact in oncology research.
Join this webinar where experts will walk attendees through the strengths of Veracyte’s Brightplex technology and how their team can help your organization uncover insights on the underlying mechanisms of therapy response and resistance at the individual and cohort level.
- IHC Assays ,
- Precision Oncology ,
- Immune-Oncology ,
- Digital Pathology ,
- Multiplex Immunohistochemistry ,
- Translational Research ,
- Translational Medicine ,
- Immunohistochemistry ,
- Tumor Microenvironment ,
- Diagnostics ,
- Biomarker Discovery ,
- IHC ,
- Cancer ,
- IHC Assay ,
- CDx ,
- Companion Diagnostics ,
- Cancer Research ,
- Biomarkers ,
- Oncology ,
- Clinical Research ,
- Immuno-Oncology ,
- Precision Medicine ,
- Drug Development
Jacques Fieschi, PhD, VP of Research & Development, Veracyte
Jacques Fieschi is the Vice President of Research & Development (R&D) at Veracyte. In this role, he leverages his extensive experience in the biotechnology industry to push the boundaries of scientific discovery in immuno-oncology. Previously, he was a key member of the R&D team at HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. Earlier in his career, Dr. Fieschi held pivotal positions in R&D at Beckman Coulter, a life sciences manufacturing company, and QIAGEN, a biotechnology research company, where he played a crucial role in advancing cutting-edge technologies. Dr. Fieschi holds a PhD from CNRS (Centre National de la Recherche Scientifique) in France. In addition, he completed post-doctoral work as a research fellow at the French Alternative Energies and Atomic Energy Commission, or CEA, a French public government-funded research organization.
Aurélie Auguste, PhD, Director, Translational Data Analysis, Veracyte
Aurélie Auguste is Director of Translational Data Analysis at Veracyte. In this role, she oversees a team of experts in bioinformatics and immuno-oncology, and she is at the forefront of cutting-edge research. Prior to this, Dr. Auguste served as a Senior Biomarker Expert at Boehringer Ingelheim, where she led translational studies in oncology and managed the Molecular Histopathology platform. Her earlier contributions include impactful work at Gustave Roussy in translational research in gynecological cancer, following her completion of a PhD at the French National Research Institute for Agriculture, Food and the Environment.
Who Should Attend?
Biopharma teams involved in immuno-oncology with responsibilities including, but not limited to:
- Biomarker discovery
- Translational medicine
- Clinical development
- CDx development
What You Will Learn
- Learn the latest advancements surrounding Veracyte’s multiplex IHC assay
- Discover how coupling IHC and ISH can help in cancer research and drug development
- Explore how spatial biology and image analysis can help provide actionable and efficient insights into the tumor microenvironment (TME)
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte engages in strategic collaborations with biopharmaceutical researchers to provide comprehensive support for their cancer drug development initiatives. In doing so, we offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics.